...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'
【24h】

OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'

机译:OP0595,一种新的二氮杂双环辛烷:作用方式作为丝氨酸β-内酰胺酶抑制剂,抗生素和β-内酰胺'增强剂'

获取原文
获取原文并翻译 | 示例

摘要

Objectives: The production of a growing diversity of beta-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji Seika Pharma and Fedora Pharmaceuticals, is a new diazabicyclooctane serine beta-lactamase inhibitor that also acts as an antibiotic and as a beta-lactamase-independent beta-lactam 'enhancer'.
机译:目的:通过革兰氏阴性细菌挑战抗微生物化疗产生β-内酰胺类生长多样性。 OP0595由Meiji Seika Pharma和Fedora Pharmaceutical分开发现,是一种新的二氮杂双环辛烷丝氨酸β-内酰胺酶抑制剂,也充当抗生素和β-内酰胺酶无依赖β-内酰胺'增强剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号